Which SSRI inhibits the enzyme CYP1A2?

Fluvoxamine is the selective serotonin reuptake inhibitor (SSRI) known to inhibit the enzyme CYP1A2. This characteristic is significant in clinical practice because CYP1A2 is involved in the metabolism of various medications, including certain antidepressants and antipsychotics. By inhibiting this enzyme, fluvoxamine can increase the levels of drugs that are metabolized by CYP1A2, potentially leading to increased effects or side effects of these medications.

Understanding the pharmacokinetics of fluvoxamine is crucial, especially when considering drug interactions in patients who may be prescribed multiple medications. This can help in tailoring pharmacotherapy to a patient's unique metabolic profile, ensuring efficacy while minimizing adverse effects. Each SSRI has a different interaction profile with cytochrome P450 enzymes, and fluvoxamine stands out in its specific activity against CYP1A2.